Introduction
Invasive fungal infections (IFIs) are a significant complication in organ transplant recipients. Among solid organ transplant recipients, liver transplant patients have one of the highest incidences and also the greatest mortality from fungal infection (1) . Consequently, based upon existing randomized clinical trials (2, 3) , both the American Society of Transplantation Infectious Diseases Community of Practice and the Infectious Disease Society of America clinical practice guidelines recommend fluconazole for liver transplant recipients at high risk for IFIs (4, 5) . A survey of liver transplant programs in North America also found that fluconazole is the most commonly used agent for antifungal prophylaxis (6) . Potential limitations of fluconazole, however, include the emergence of fluconazole-resistant nonalbicans Candida species as pathogens, lack of activity for Aspergillus, and drug interactions with immunosuppressive agents leading to adverse events.
The echinocandins have activity for both Aspergillus and Candida species, including many Candida species resistant to fluconazole. The echinocandins also have a favorable safety profile and a low potential for drug interactions. Similar to the azoles, the echinocandins are both fungicidal and synergistic in combination with calcineurin-inhibitor agents for common fungal pathogens (7) . In small uncontrolled studies, prophylaxis with caspofungin or micafungin appeared to be well-tolerated in liver transplant recipients (8) (9) (10) . Anidulafungin is unique among echinocandins in that it is eliminated almost exclusively via biotransformation by nonenzymatic degradation in the blood without hepatic or renal elimination (11) . Therefore, we conducted the first randomized, double-blind trial of an echinocandin for antifungal prophylaxis in solid organ transplant recipients by comparing anidulafungin with fluconazole for prevention of IFIs in high-risk liver transplant patients.
Methods

Study design
This was a randomized, double-blind trial involving liver transplant recipients at high risk for IFIs conducted between February 2010 and November 2011. The study was approved by the institutional review board at each participating site. Written informed consent was obtained from all patients or their legally authorized representatives.
Patients
Liver transplant patients !18 years of age who had one or more of the following risk factors for IFI were eligible for the study: retransplantation; transplantation for fulminant hepatic failure; receipt of corticosteroids for at least 2 weeks within 4 weeks preceding transplantation; hospitalization for at least 48 h in the intensive care unit (ICU) at the time of transplantation; colonization with Candida species at !2 sites within 4 weeks preceding transplantation; !15 U of intraoperative packed red blood cell transfusions and operative time >6 h; requirement of any form of renal replacement therapy at the time or within 7 days of transplantation; and reoperation involving the intraabdominal cavity. These variables as risk factors for IFIs in liver transplant recipients have been identified in multiple previous studies (2, (12) (13) (14) (15) (16) (17) (18) . Patients were excluded if they had known hypersensitivity to the azoles or the echinocandins; had life expectancy of <72 h; or had received systemic antifungal therapy for an IFI within 4 weeks preceding transplantation.
Blinding and study drug administration
Eligible patients were randomized 1:1 to receive either anidulafungin or fluconazole using permuted block randomization. Randomization was stratified within each center by Model for End-Stage Liver Disease (MELD) !30 and pretransplant receipt of an antifungal agent within 30 days prior to transplantation. Dosing with the study drug had to commence within 5 days of transplantation. Anidulafungin was administered as a 200 mg intravenous loading dose followed by 100 mg intravenous daily. There was no adjustment of the anidulafungin dosage for renal failure. Fluconazole was administered at a dosage of 400 mg intravenously daily. The fluconazole dosage was adjusted for renal failure as follows: creatinine clearance <50 mL/min and no dialysis (200 mg intravenously daily); continuous renal replacement therapy (400 mg intravenously daily); intermittent hemodialysis (400 mg intravenously after hemodialysis on dialysis days and saline infusion without fluconazole on nondialysis days). To maintain blinding, the study drug was dispensed in identical infusion bags with the same volume of fluid. Except for the site pharmacists, patients, research staff, and all members of the clinical team remained masked to drug assignment throughout the study.
The study drugs were continued for 21 days or until discharge. If a patient was discharged from the hospital before completion of 21 days of the study drug, the study drug was discontinued. In patients with ongoing need for renal replacement therapy, persistent liver allograft dysfunction, continued ICU stay, or increased immunosuppression for rejection in the previous 21 days, study drug could be continued beyond 21 days for a maximum of 42 days.
Assessments
The primary end point was the incidence of proven or probable IFIs within 90 days of transplantation. IFIs were defined by using the criteria of the European Organization for Research and Treatment of Cancer/ Mycoses Study Group (EORTC/MSG) (19) . Other assessments included fungal-free survival, fungal colonization, rejection, graft loss, and all-cause mortality. Fungal colonization was defined as previously reported in liver transplant recipients (2) . Fungal isolates causing IFIs were tested for in vitro susceptibility to antifungal agents by a microbroth dilution assay, in accordance with Clinical Laboratory Standards Institute guidelines (20, 21) . Adverse events were recorded until 7 days after the last dose of study drug. Independent on-site clinical monitoring was conducted for source data verification and safety assessments. An independent data and safety monitoring committee provided study oversight.
Statistical analyses
IFIs have been documented in 36-50% of high-risk liver transplant recipients (14, (22) (23) (24) . Among patients receiving prophylactic fluconazole, 14-23% and an average of 18% developed IFIs (14, 22, 24) . In a noncomparative study of prophylactic caspofungin in high-risk liver transplant recipients, 2.8% developed IFIs (8). Thus, assuming an incidence of IFI of 18% in the fluconazole group and 4% in the anidulafungin group, a sample size of 182 patients (91 patients in each group) would detect the aforementioned difference with a power of 80% and a ¼ 0.05. Adjusting for a 10% drop out rate, the study would require a total of 200 patients or 100 patients per study group.
Stata/IC (College Station, TX) was used for statistical analyses. Baseline characteristics and risk factors were compared using the chi-square test or rank sum test. The Mantel-Haenszel odds ratio was used to evaluate the effect of treatment on IFIs in a modified intent-to-treat (M-ITT) population (randomized patients with no baseline IFI and received >48 h of study drug). Breakthrough infections, defined as IFIs occurring during receipt of study drug, were similarly evaluated. The odds of any IFI or only breakthrough IFI in specific high-risk groups was assessed by the Mantel-Haenszel test.
A Kaplan-Meier estimate was calculated to evaluate the time to IFIs. Fungalfree survival between the two groups was compared using a log rank test. Patients who died without evidence of IFI were censured at the date of death. All remaining patients were censored at day 90 after transplant. The analysis was repeated using the stratification variables. The Kaplan-Meier estimate was also used to evaluate all-cause mortality. For this analysis, the entry point was the day of transplant, and the end point was date of death. Survivors were censored at day 90 after transplant.
Results
Patient characteristics
A total of 200 high-risk liver transplant recipients were randomized to receive either fluconazole or anidulafungin (100 patients per group). The two groups were similar in terms of demographic characteristics and risk factors for IFIs (Table 1) . Approximately, 75% of the patients in each group had a MELD !30, while 60% in each group required renal replacement therapy. The median duration of prophylaxis was 21 days for both fluconazole (range, 5-43) and anidulafungin patients (range, 5-46). Thirty-six fluconazole patients received <21 days of study drug due to early discharge from the hospital (31 patients), early death after transplantation (1 patient), development of an IFI (2 patients) or withdrawal of study drug by the primary physician (2 patients). Similarly, 42 anidulafungin patients received <21 days of study drug due to early discharge from the hospital (37 patients), early death (2 patients), development of an IFI (2 patients) or possible adverse event related to study drug (1 patient).
Efficacy
Two patients randomized to the anidulafungin group were subsequently found to have invasive aspergillosis at time of initiation of study drug and received <48 h of anidulafungin. Another patient randomized to fluconazole was withdrawn on study day 1 by the primary physician and received less than 24 h of fluconazole. These three patients were excluded from the M-ITT population used for efficacy analyses. As shown in Table 2 , IFIs developed in 8% of fluconazole and in 5.1% of anidulafungin patients (p ¼ 0.40). In the fluconazole group, there were six cases of invasive candidiasis (all caused by nonalbicans Candida species) and two cases of invasive aspergillosis. All the IFIs in the anidulafungin group were due to Candida species. No patients developed invasive aspergillosis on prophylactic anidulafungin. The median time from initiation of study drug to onset of IFI was longer in the anidulafungin group (43 days, range 7-87) compared to the fluconazole group (29 days, range 8-76), however this difference was not statistically significant (p ¼ 0.35). Breakthrough IFIs on study drug occurred in two anidulafungin patients (2.0%) and in five fluconazole patients (5.0%). Among patients who had received a systemic antifungal agent prior to transplantation (fluconazole in all cases), breakthrough IFIs occurred in none of 14 anidulafungin patients but in 3 of 11 None of the differences between study groups were statistically significant (p > 0.05) by chi-square test or rank sum test. For renal replacement therapy, intensive care stay, and blood loss, p-values were 0.35, 0.07, and 0.14, respectively. Some patients had more than one underlying liver disease. 3 There was no significant difference between the study groups, p ¼ 0.756 by chi-square test. 
Modified intent-to-treat population excludes one fluconazole patient withdrawn on study day 1 by primary physician and two anidulafungin patients found to have invasive aspergillosis at study entry. Two C. glabrata infections, one C. krusei fungemia and both cases of invasive aspergillosis in the fluconazole group and one case each of C. glabrata and C. albicans fungemia in the anidulafungin group were breakthrough infections occurring during receipt of study drug. Other fungal infections occurred after the study drug administration period. 4 One fluconazole patient had abdominal abscess with both C. glabrata and C. kefyr.
fluconazole patients (27.3%) (p ¼ 0.07). The risk for IFI with anidulafungin prophylaxis compared to fluconazole prophylaxis by prespecified established risk factors for IFI is summarized in Table 3 . For all subgroups, there were no significant differences in the overall risk for IFI between anidulafungin patients and fluconazole patients. However, for patients who had a MELD score !30, required renal replacement therapy, were given >15 U of packed red blood cells during transplant surgery, or had received fluconazole before transplantation, there was a lower risk for a breakthrough IFI with anidulafungin prophylaxis. Similarly, there were no significant differences in serum creatinine and liver function tests between the two study groups. Adverse events leading to discontinuation of the Any IFI within 90 days of starting study drug or breakthrough infection while receiving study drug. 3 Exact CI not calculated due to no breakthrough IFI in the anidulafungin group; fixed effect correction added to estimate CI.
Fungal colonization
Antifungal Prophylaxis in Liver Transplants
study drug occurred in 1 (1%) of 98 patients in the anidulafungin group (prolonged QT interval) and in none of the 99 fluconazole patients (p ¼ 0.99).
Other outcomes and mortality
The incidence of rejection within 90 days of transplantation was similar in the fluconazole and anidulafungin groups (4% vs. 6%, p ¼ 0.51). Kaplan-Meier estimates of fungal-free survival showed no significant difference between the anidulafungin group (94.5%; 95% CI, 87.4-97.7) and the fluconazole group (91.3%; 95% CI, 83.3-95.5, p ¼ 0.93). The overall mortality rate at 90 days after transplantation was 12% in each study group. Causes of death in the study groups are shown in Table 4 . There were no deaths due to an IFI.
Discussion
IFIs occur in 36-50% of high-risk liver transplant recipients without any effective antifungal prophylaxis (14, (22) (23) (24) . In the only previous randomized, double-blind trial of antifungal prophylaxis in liver transplant patients almost two decades ago, fluconazole compared to placebo significantly reduced IFIs (2) . Since this pivotal study, there have been very few additional definitive clinical trials of antifungal prophylaxis in liver transplant patients or other types of solid organ transplant recipients. Similarly, despite the favorable profile of the echinocandins for antifungal prophylaxis, there have been no previous randomized, double-blind, controlled studies of an echinocandin for prevention of IFIs in organ transplant recipients or other types of complex surgical patients.
In randomized trials involving oncology patients receiving either a stem cell transplant or chemotherapy, both micafungin and caspofungin were as effective as fluconazole or itraconazole for antifungal prophylaxis (25) (26) (27) . We also found that the overall incidence of IFIs in high-risk liver transplant recipients was similar for patients receiving a prophylactic echinocandin (anidulafungin) or fluconazole. The incidence of IFIs in our patients receiving prophylactic anidulafungin (5%) was similar to the incidence reported in previous small, noncontrolled studies of echinocandin prophylaxis in high-risk liver transplant recipients and close to the 4% incidence used to calculate our study's sample size (8) (9) (10) . However, despite the inclusion of many extremely ill patients (MELD ! 30 in 75% of the patients) with well-established risk factors for IFI in our study, the incidence of IFI in patients receiving prophylactic fluconazole was 8% and lower than the expected incidence of 18%, which was based on existing data from studies done more than a decade ago (14, (22) (23) (24) . Indeed, despite the increasing acuity and sickness of patients currently undergoing liver transplantation, both patient and graft survival have improved due to advances in immunosuppression, patient management, and surgical experience (28) . These factors may have contributed to the lower than expected incidence of IFI in the fluconazole patients. It is also possible that current risk factors for IFI in liver transplant recipients may differ from those risk factors previously identified in earlier studies. In two recent multivariate analyses of risk factors in the MELD era of liver transplantation, a MELD score !30 was found to be the most influential factor for IFI (17, 18) . The incidence of probable or proven IFI in these two studies were 28% and 24%, respectively.
Based on the incidence of IFI in our study (5.1% with anidulafungin, 8% with fluconazole) involving very sick liver transplant patients with established risk factors for IFI, an extremely large sample size ($1125 patients per study group or 2250 total patients) would be needed to demonstrate a statistically significant difference in the incidence of IFI (29) . As such, it is unlikely that such a large randomized, double-blind trial comparing an echinocandin with fluconazole for antifungal prophylaxis would be feasible.
Anidulafungin is active against Aspergillus as well as several fluconazole-resistant Candida species. The incidence of Aspergillus infection or colonization was lower in our patients receiving anidulafungin (3% vs. 9%, p ¼ 0.08).
In addition, more Candida species causing invasive candidiasis in our study were resistant to fluconazole (five isolates) than to anidulafungin (none of the isolates).
There was a higher incidence of breakthrough IFIs among fluconazole patients (27%) compared to anidulafungin patients (no patients; p ¼ 0.07) who had received fluconazole before transplantation. These data suggest that anidulafungin may be more beneficial for antifungal prophylaxis in patients at higher risk for Aspergillus infection or who were treated with fluconazole before transplantation. Table 3 ). However, three anidulafungin patients developed candidemia caused by Candida organisms still sensitive to anidulafungin after completing 42 days of anidulafungin prophylaxis. Thus, in clinical practice, prophylaxis with anidulafungin or another effective antifungal agent will likely need to be continued for a longer period if the patient still has persistent risk factors for IFIs.
Adverse events were similar with anidulafungin and fluconazole. Both drugs were generally well-tolerated. Fluconazole in liver transplant recipients increases serum cyclosporine levels (2) and was associated with higher serum tacrolimus levels in this study. However, there was no increase in tacrolimus nephrotoxicity or neurotoxicity with fluconazole. Neither fluconazole nor anidulafungin had any apparent hepatotoxicity.
A recent meta-analysis found that antifungal prophylaxis in liver transplant recipients does not affect overall mortality despite a significant reduction of IFI as well as mortality attributable to fungal infection (3). Since IFI frequently occur in critically ill liver transplant recipients with underlying host factors (graft dysfunction, surgical complications, multiorgan failure) that also greatly influence survival, this finding is not surprising. In our study, the overall mortality rate at 90 days after transplantation was low (12% in each study group), and there were no deaths due to IFI. Frequent protocol-driven diagnostic studies in patients with suspected fungal infection and subsequent initiation of early appropriate antifungal therapy in patients with documented IFI may have contributed to the absence of fungal-related mortality.
The decision to use antifungal prophylaxis needs to consider the possible emergence of resistant organisms and cost (30) . An increase in Candida krusei and Candida glabrata infections has been associated with the use of prophylactic fluconazole in some studies (31, 32) . There has also been an increasing number of reports of echinocandinresistant Candida infections (33) . Consequently, antifungal prophylaxis in transplant recipients is frequently targeted to high-risk patients with established risk factors for IFI (6) . Similarly, the significantly higher cost of an echinocandin, which must be given intravenously, needs to be balanced against the lower cost of fluconazole, which has the convenience of both oral and intravenous administration. A prophylactic strategy currently recommended for stem cell transplant recipients, in which fluconazole is given for initial prophylaxis and an echinocandin or mold-active azole is reserved for patients at risk for Aspergillus infections or fluconazole-resistant Candida infections, may also be the most cost-effective approach for liver transplant recipients (34).
In conclusion, for most liver transplant recipients at high risk for IFIs, anidulafungin and fluconazole have similar efficacy for antifungal prophylaxis. Both anidulafungin and fluconazole are well-tolerated in liver transplant recipients. Prophylaxis with anidulafungin may be beneficial in patients who are at high risk for invasive Aspergillus or have received fluconazole prior to transplantation.
